drugset

drugset / Trial / NCT07180771

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

NCT07180771 ↗

Phase 2 Not yet recruiting 44 enrolled Boryung Pharmaceutical Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).

Timeline

Start: 2026-02
Primary completion: 2027-09
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bosmolisib	Small molecule	200 mg	Oral

Indications